MX2018002237A - Nuevos biomarcadores y metodos para tratar el cancer. - Google Patents

Nuevos biomarcadores y metodos para tratar el cancer.

Info

Publication number
MX2018002237A
MX2018002237A MX2018002237A MX2018002237A MX2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A
Authority
MX
Mexico
Prior art keywords
methods
inhibitors
gene
treatment
pi3k pathway
Prior art date
Application number
MX2018002237A
Other languages
English (en)
Inventor
Avivar Valderas Alvaro
Humberto CRUZALEGUI Francisco
Hudson Kevin
Kenneth MCEWEN Robert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018002237A publication Critical patent/MX2018002237A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen biomarcadores para el tratamiento de afecciones patológicas asociadas con la vía de PI3K tales como el cáncer y métodos para utilizar inhibidores de componentes anteriores de la vía de PI3K tales como los inhibidores de PI3K-a o inhibidores de AKT. En particular, se describen biomarcadores para la selección de pacientes en el tratamiento del cáncer, así como métodos de tratamiento terapéutico, kits diagnósticos y métodos de detección, donde los tipos de cáncer que poseen una mutación en un componente anterior de la vía de PI3K (tal como el gen PIK3CA y/o el gen AKT) y un gen MAP3K1 y un gen MAP2K4 naturales tienen más probabilidad de responder favorablemente al tratamiento con inhibidores de los componentes anteriores de la vía de PI3K.
MX2018002237A 2015-09-17 2016-09-16 Nuevos biomarcadores y metodos para tratar el cancer. MX2018002237A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219698P 2015-09-17 2015-09-17
PCT/EP2016/072069 WO2017046394A1 (en) 2015-09-17 2016-09-16 Novel biomarkers and methods of treating cancer

Publications (1)

Publication Number Publication Date
MX2018002237A true MX2018002237A (es) 2018-03-23

Family

ID=57068049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002237A MX2018002237A (es) 2015-09-17 2016-09-16 Nuevos biomarcadores y metodos para tratar el cancer.

Country Status (16)

Country Link
US (1) US11685953B2 (es)
EP (1) EP3350346B1 (es)
JP (1) JP2018531223A (es)
KR (1) KR20180049093A (es)
CN (1) CN108026587A (es)
AU (1) AU2016325030A1 (es)
BR (1) BR112018004207A2 (es)
CA (1) CA2997206A1 (es)
EA (1) EA201890649A1 (es)
ES (1) ES2939809T3 (es)
HK (1) HK1251927A1 (es)
IL (1) IL257836A (es)
MX (1) MX2018002237A (es)
TW (1) TW201726140A (es)
WO (1) WO2017046394A1 (es)
ZA (1) ZA201802481B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020041684A1 (en) * 2018-08-23 2020-02-27 Memorial Sloan-Kettering Cancer Center Biomarkers for determining responsiveness of a cancer to pi3k inhibitors
CN111304326B (zh) * 2020-02-22 2021-03-23 四川省人民医院 检测及靶向lncRNA生物标志物的试剂及其在肝细胞癌中的应用
CN111334580A (zh) * 2020-04-16 2020-06-26 中山大学达安基因股份有限公司 Pik3ca基因突变检测试剂盒
CN113151472A (zh) * 2021-04-28 2021-07-23 北华大学 胃癌诊断标志物及其应用
CN114470152B (zh) * 2022-02-21 2022-09-02 黑龙江中医药大学 基于srebp-1/pi3k/akt信号通路调控乳腺癌增殖迁移的抑制剂及其应用
CN114525344A (zh) * 2022-04-22 2022-05-24 普瑞基准科技（北京）有限公司 一种用于检测或辅助检测肿瘤相关基因变异的试剂盒及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ES2648388T3 (es) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
MY150059A (en) * 2007-10-11 2013-11-29 Astrazeneca Ab Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
US20100298286A1 (en) 2007-12-20 2010-11-25 Novartis Ag Organic Compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2640367A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
AU2012340186A1 (en) * 2011-11-18 2014-06-19 Vanderbilt University Markers of triple-negative breast cancer and uses thereof
US8892132B2 (en) * 2012-09-05 2014-11-18 Motorola Solutions, Inc. Analytic and tracking systems and methods using over-the-air identifiers of mobile devices
WO2014089241A2 (en) * 2012-12-04 2014-06-12 Caris Mpi, Inc. Molecular profiling for cancer
AU2014208964B2 (en) * 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
WO2017046394A1 (en) 2017-03-23
TW201726140A (zh) 2017-08-01
US20210130901A1 (en) 2021-05-06
ES2939809T3 (es) 2023-04-27
JP2018531223A (ja) 2018-10-25
AU2016325030A1 (en) 2018-05-10
EP3350346A1 (en) 2018-07-25
BR112018004207A2 (pt) 2018-09-25
IL257836A (en) 2018-04-30
KR20180049093A (ko) 2018-05-10
EP3350346B1 (en) 2023-01-04
CA2997206A1 (en) 2017-03-23
HK1251927A1 (zh) 2019-05-03
EA201890649A1 (ru) 2018-08-31
US11685953B2 (en) 2023-06-27
ZA201802481B (en) 2019-01-30
CN108026587A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2018002237A (es) Nuevos biomarcadores y metodos para tratar el cancer.
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
MX2022005473A (es) Metodos y composiciones para tratar canceres resistentes al inhibidor de la via de cinasas proteicas activadas por mitogeno (mapk), no cinasas extracelulares de se?al regulada (erk).
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2014144777A3 (en) Lipids that increase insulin sensitivity and methods of using the same
MX2016008042A (es) Derivados de imidazopirazinona.
PH12021550035A1 (en) Combination therapy
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
WO2013081645A3 (en) Erbb3 mutations in cancer
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker
MX2015010776A (es) Metodos y composiciones para detectar y tratar mutantes de akt resistentes a farmacos.
WO2013169771A3 (en) Methods and compositions for the prognosis and treatment of relapsed leukemia
WO2015112809A3 (en) Nsd3 inhibitors for treatment of cancers
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
MX2022008843A (es) Metodos para tratar cancer con inhibidores de farnesiltransferasa.